Takeda Oncology
Saleh El-husayni is a seasoned professional in clinical biomarker operations and translational development, currently serving as the Clinical Biomarker Operations Lead at Takeda Oncology. With a robust background that includes roles as an Operations Scientist at Sana Biotechnology, Project Manager at Editas Medicine, and Senior Clinical Research Associate at Sarepta Therapeutics, Saleh has extensive experience in overseeing bioanalytical assay development, regulatory submissions, and cross-department collaborations. Previous contributions include leading clinical trial analyses, managing vendor contracts, and facilitating training for clinical sites, all while ensuring compliance with GCLP guidelines. Saleh's academic foundation is a Bachelor of Science in Biochemistry from Northeastern University.
This person is not in any teams
This person is not in any offices
Takeda Oncology
21 followers
In 2008, Takeda Pharmaceutical Company Limited acquired Millennium Pharmaceuticals and the resulting company became exclusively focused on oncology. In 2014, Takeda Oncology was created to become the global headquarters for Takeda’s oncology specialty business unit, in Cambridge, Massachusetts, on the former Millennium Pharmaceuticals site. AtTakeda Oncology they endeavor to deliver novel medicines to patients with cancer worldwide through our commitment to science, breakthrough innovation and passion for improving the lives of patients. This singular focus drives our aspirations to discover, develop and deliver breakthrough oncology therapies. By concentrating the power of leading scientific minds and the vast resources of a global pharmaceutical company, they are finding innovative ways to improve the treatment of cancer.They've built a portfolio of paradigm-changing therapies and a leading oncology pipeline. Though They've made great strides in our fight against cancer, they are determined to do more — to work harder and to reach higher. They continue to seek our aspirations with the same passion, agility and entrepreneurial spirit that has sustained our patient-centric culture and has made us the leaders in oncology that they are today.